Background The conventional 8 mg/kg tocilizumab (TCZ) dose regimen for rheumatoid arthritis (RA) yields higher serum trough concentrations (TCZtrough) than needed (> 1 mg/L) for C-reactive protein normalization and disease control. We evaluated the registered dosing approach by TCZtrough assessment using pharmacokinetic (PK) modelling and introduced a practical TCZtrough-guided dose reduction nomogram. Methods This prospective cohort study examined RA patients with stable disease activity undergoing intravenous TCZ treatment. A population PK model was constructed utilizing literature PK-data, TCZtrough, and dosing information. The derived model enabled prediction of TCZtrough guided dose de-escalation constructed in a nomogram. Dose reduction was implemented in a study subgroup, involving a reassessment of TCZtrough and maintenance of disease activity control. Results In 39 patients treated according to the registered dose-scheme, the baseline mean TCZtrough was 27.6 mg/L (SD 12.6). Simulations using the constructed PK-model demonstrated that a 0.4–4.6 mg/kg dose reduction was feasible in 36 patients (92%). The simulated reduction corresponds with an annual cost-reduction of approximately 25% per patient. Twelve consecutive patients were selected for the prospective validation of a model-based dose reduction nomogram. In all patients TCZtrough remained above 1 mg/L upon reduction, while the median TCZtrough decreased by 25 mg/L. After 18 months, 75% (n = 9) of these patients continued to receive reduced TCZ dosages, while maintaining stable disease. Conclusions TCZtrough guided dose de-escalation based on a proposed nomogram results in considerable cost reductions, while efficacy is maintained in most patients. Through routine monitoring of TCZtrough in stable RA patients, dose reduction can be implemented, potentially leading to optimization of cost-effective TCZ therapy. <Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry align="left" nameend="c2" namest="c1"> Key Points • Tocilizumab (TCZ) levels at a registered dosage (8 mg/kg) substantially exceed the minimally required concentration for disease control. • Although the pharmacokinetics of TCZ are well established, TCZ trough levels (TCZtrough) are rarely used to guide individualized dose reduction strategies in routine RA practice. • When reducing TCZ use, dose reduction is preferred above extending the dose interval for achieving sufficient TCZtrough. • Dose de-escalation based on TCZtrough measurement and a nomogram leads to a substantial dose reduction while maintaining efficacy, potentially reducing TCZ costs by 25%. </entry> </row> </tbody> </tgroup> </Table>

Cost optimizing tocilizumab therapy in stable rheumatoid arthritis: a dose de-escalation nomogram to prevent overuse and unnecessary costs

期刊论文
发表日期：

2025年11月13日

查看全文

Kaja van Soest,
Sofia Ramiro,
Mirian J. F. Starmans-Kool,
Nieko C. Punt,
Robert B. M. Landewé,
Niels W. Boone

摘要

Background

The conventional 8 mg/kg tocilizumab (TCZ) dose regimen for rheumatoid arthritis (RA) yields higher serum trough concentrations (TCZ_trough) than needed (> 1 mg/L) for C-reactive protein normalization and disease control. We evaluated the registered dosing approach by TCZ_trough assessment using pharmacokinetic (PK) modelling and introduced a practical TCZ_trough-guided dose reduction nomogram.

Methods

This prospective cohort study examined RA patients with stable disease activity undergoing intravenous TCZ treatment. A population PK model was constructed utilizing literature PK-data, TCZ_trough, and dosing information. The derived model enabled prediction of TCZ_trough guided dose de-escalation constructed in a nomogram. Dose reduction was implemented in a study subgroup, involving a reassessment of TCZ_trough and maintenance of disease activity control.

Results

In 39 patients treated according to the registered dose-scheme, the baseline mean TCZ_trough was 27.6 mg/L (SD 12.6). Simulations using the constructed PK-model demonstrated that a 0.4–4.6 mg/kg dose reduction was feasible in 36 patients (92%). The simulated reduction corresponds with an annual cost-reduction of approximately 25% per patient.

Twelve consecutive patients were selected for the prospective validation of a model-based dose reduction nomogram. In all patients TCZ_trough remained above 1 mg/L upon reduction, while the median TCZ_trough decreased by 25 mg/L. After 18 months, 75% (n = 9) of these patients continued to receive reduced TCZ dosages, while maintaining stable disease.

Conclusions

TCZ_trough guided dose de-escalation based on a proposed nomogram results in considerable cost reductions, while efficacy is maintained in most patients. Through routine monitoring of TCZ_trough in stable RA patients, dose reduction can be implemented, potentially leading to optimization of cost-effective TCZ therapy.

Key Points

• Tocilizumab (TCZ) levels at a registered dosage (8 mg/kg) substantially exceed the minimally required concentration for disease control.

• Although the pharmacokinetics of TCZ are well established, TCZ trough levels (TCZtrough) are rarely used to guide individualized dose reduction strategies in routine RA practice.

• When reducing TCZ use, dose reduction is preferred above extending the dose interval for achieving sufficient TCZtrough.

• Dose de-escalation based on TCZtrough measurement and a nomogram leads to a substantial dose reduction while maintaining efficacy, potentially reducing TCZ costs by 25%.